Survival and Proliferation Factors of Normal and Malignant Plasma Cells

  • Bernard Klein
  • Karin Tarte
  • Michel Jourdan
  • Karene Mathouk
  • Jerome Moreaux
  • Eric Jourdan
  • Eric Legouffe
  • John De Vos
  • Jean François Rossic


Since the first identification of interleukin (IL)-6 as a myeloma cell growth factor by Dr. Kawano’s and Dr. Klein’s groups 14 years ago, numerous studies have emphasized its major roles in the emergence of malignant plasma cells in vivo and in the generation of normal plasma cells. Four transcription factors control B-cell differentiation into plasma cells. The B-cell transcription factor pax-5 is mainly responsible for a B-cell phenotype, andbcl-6 represses the plasma cell transcription factor blimp-1 and plasma cell differentiation.bcl-6 expression is triggered by CD40 and IL-4 activation. A lack of CD40 and IL-4 activation yields a down-regulation ofbcl-6 expression, and IL-6 stimulation yields an up-regulation of blimp-1, mainly through STAT3 activation. Blimp-1 further down-regulatesbcl-6 andpax-5 expression and makes plasma cell differentiation possible. IL-6 as well as IL-10 up-regulate XBP-1. XBP-1 is another transcription factor that is involved in plasma cell differentiation and whose gene expression is shut down by pax-5.The plasma cell transcription factors blimp-1 and XBP-1 are up-regulated, and the B-cell transcription factors bcl-6 and pax-5 are down-regulated, in malignant cells compared to B-cells. Apart from the recent identification of these 4 transcription factors, the factors involved in normal plasma cell generation are mostly unknown. Regarding malignant plasma cells, 3 categories of growth factors have been identified: (1) the IL-6 family cytokines, IL-10, and interferon α that activate the Janus kinase—signal transducer and activator of transcription (JAK/STAT) and mitogen-activated protein (MAP) kinase pathways; (2) growth factors activating the phosphatidylinositol (PI)-3 kinase/AKT and MAP kinase pathways, unlike the JAK/STAT pathway (insulin-like growth factor 1, hepatocyte growth factor, and members of the epidermal growth factor family able to bind syndecan-1 proteoglycan); and (3) B-cell—activating factor (BAFF) or proliferationinducing ligand (APRIL) that activate the nuclear factor κB and PI-3 kinase/AKT pathways.BAFF and APRIL bind to BAFF receptor and TACI and are major B-cell survival factors. Recent data indicate that these various growth factors may cooperate to provide optimum signaling because they are localized together and with cytoplasmic transduction elements in caveolinlinked membrane caveolae. The identification of these myeloma cell growth factors and of the associated transduction pathways should provide novel therapeutic targets in multiple myeloma.

Key words

Myeloma IL-6 IGF-1 HGF EGF BAFF 


  1. 1.
    Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.Blood. 1999;94:701–712.PubMedGoogle Scholar
  2. 2.
    Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.Blood. 2002;100:1113–1122.PubMedGoogle Scholar
  3. 3.
    Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells.Annu Rev Immunol. 2003;21:205–230.PubMedCrossRefGoogle Scholar
  4. 4.
    Jung J, Choe J, Li L, Choi YS. Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL-10.Eur J Immunol. 2000;30:2437–2443.PubMedCrossRefGoogle Scholar
  5. 5.
    Agematsu K, Nagumo H, Oguchi Y, et al. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction.Blood. 1998;91:173–180.PubMedGoogle Scholar
  6. 6.
    Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.Science. 1988;241:825–828.PubMedCrossRefGoogle Scholar
  7. 7.
    Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice.Proc Natl Acad Sci U S A. 1989;86:7547–7551.PubMedCrossRefGoogle Scholar
  8. 8.
    Kopf M, Baumann H, Freer G, et al. Impaired immune and acutephase responses in interleukin-6-deficient mice.Nature. 1994;368:339–342.PubMedCrossRefGoogle Scholar
  9. 9.
    Wen XY, Stewart AK, Sooknanan RR, et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.Int J Oncol. 1999;15:173–178.PubMedGoogle Scholar
  10. 10.
    Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1.Nature. 2001;412:300–307.PubMedCrossRefGoogle Scholar
  11. 11.
    Hirano T. Interleukin 6 and its receptor: ten years later.Int Rev Immunol. 1998;16:249–284.PubMedCrossRefGoogle Scholar
  12. 12.
    Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma.Nature. 1988;332:83–85.PubMedCrossRefGoogle Scholar
  13. 13.
    Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.Blood. 1989;73:517–526.PubMedGoogle Scholar
  14. 14.
    Zhang XG, Bataille R, Widjenes J, Klein B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.Cancer. 1992;69:1373–1376.PubMedCrossRefGoogle Scholar
  15. 15.
    Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.Blood. 1991;78:1198–1204.PubMedGoogle Scholar
  16. 16.
    Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of antiinterleukin-6 (IL-6) murine monoclonal antibody in advanced multiple myeloma.Blood. 1995;86:685–691.PubMedGoogle Scholar
  17. 17.
    Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.Blood. 1995;86:3123–3131.PubMedGoogle Scholar
  18. 18.
    Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias.J Clin Invest. 1989;84:2008–2011.PubMedCrossRefGoogle Scholar
  19. 19.
    Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.Eur J Immunol. 1993;23:820–824.PubMedCrossRefGoogle Scholar
  20. 20.
    Portier M, Rajzbaum G, Zhang XG, et al. In vivo interleukin-6 gene expression in the tumoral environment in multiple myeloma.Eur J Immunol. 1991;21:1759–1762.PubMedCrossRefGoogle Scholar
  21. 21.
    Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production.Br J Haematol. 1998;103:1152–1160.PubMedCrossRefGoogle Scholar
  22. 22.
    Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.Proc Natl Acad Sci U S A. 1996;93:4885–4890.PubMedCrossRefGoogle Scholar
  23. 23.
    Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.Blood. 1993;82:3712–3720.PubMedGoogle Scholar
  24. 24.
    Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.Blood. 1994;84:2269–2277.PubMedGoogle Scholar
  25. 25.
    Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.Blood. 1994;83:3654–3663.PubMedGoogle Scholar
  26. 26.
    Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin-6 transgenic mice.Proc Natl Acad Sci U S A. 1989;86:7547–7551.PubMedCrossRefGoogle Scholar
  27. 27.
    Suematsu S, Matsusaka T, Matsuda T, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.Proc Natl Acad Sci U S A. 1992;89:232–235.PubMedCrossRefGoogle Scholar
  28. 28.
    Lattanzio G, Libert C, Aquilina M, et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.Am J Pathol. 1997;151:689–696.PubMedGoogle Scholar
  29. 29.
    Zhang XG, Gu ZJ, Lu ZY, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.J Exp Med. 1994;179:1337–1342.PubMedCrossRefGoogle Scholar
  30. 30.
    Klein B. Growth factors in the pathogenesis of multiple myeloma. In: Garthon L, Durie BGM, eds.Multiple Myeloma. London: Edward Arnold Publishers; 1996:73–82.Google Scholar
  31. 31.
    Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. IFN-alpha induced autocrine production of IL-6 in myeloma cell lines.J Immunol. 1991;147:4402–4407.PubMedGoogle Scholar
  32. 32.
    Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis.J Immunol. 1998;161:2692–2699.PubMedGoogle Scholar
  33. 33.
    Arora T, Jelinek DF. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression.J Biol Chem. 1998;273:11799–11805.PubMedCrossRefGoogle Scholar
  34. 34.
    Lu ZY, Zhang XG, Wijdenes J, et al. Interleukin-10 is a growth factor for human myeloma cells.Blood. 1995;85:2521–2527.PubMedGoogle Scholar
  35. 35.
    Gu ZJ, Costes V, Lu ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.Blood. 1996;88:3972–3986.PubMedGoogle Scholar
  36. 36.
    De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogenactivated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.Br J Haematol. 2000;109:823–828.PubMedCrossRefGoogle Scholar
  37. 37.
    Jourdan M,Vos JD, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.Cell Death Differ. 2000;7:1244–1252.PubMedCrossRefGoogle Scholar
  38. 38.
    Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.Immunity. 1999;10:105–115.PubMedCrossRefGoogle Scholar
  39. 39.
    Puthier D, Derenne S, Barille S, et al. Mcl-1 and bcl-xL are co-regulated by IL-6 in human myeloma cells.Br J Haematol. 1999;107:392–395.PubMedCrossRefGoogle Scholar
  40. 40.
    Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.Blood. 2002;100:194–199.PubMedCrossRefGoogle Scholar
  41. 41.
    Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.Oncogene. 2003;22:2950–2959.PubMedCrossRefGoogle Scholar
  42. 42.
    Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/ AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.Cancer Res. 2000;60:6763–6770.PubMedGoogle Scholar
  43. 43.
    Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor.Science. 1997;276:1418–1420.PubMedCrossRefGoogle Scholar
  44. 44.
    Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.Oncogene. 2002;21:5673–5683.PubMedCrossRefGoogle Scholar
  45. 45.
    Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.Blood. 2002;99:4138–4146.PubMedCrossRefGoogle Scholar
  46. 46.
    Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.Oncogene. 2002;21:6587–6597.PubMedCrossRefGoogle Scholar
  47. 47.
    Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulinlike growth factor I is a growth and survival factor in human multiple myeloma cell lines.Blood. 1996;88:2250–2258.PubMedGoogle Scholar
  48. 48.
    Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth.J Immunol. 1997;159:487–496.PubMedGoogle Scholar
  49. 49.
    Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.Br J Haematol. 2000;111:626–634.PubMedCrossRefGoogle Scholar
  50. 50.
    Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth.Blood. 2000;96:2856–2861.PubMedGoogle Scholar
  51. 51.
    Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.Oncogene. 2001;20:5991–6000.PubMedCrossRefGoogle Scholar
  52. 52.
    Hsu JH, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses.Oncogene. 2002;21:1391–1400.PubMedCrossRefGoogle Scholar
  53. 53.
    Ge NL, Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.Oncogene. 2000;19:4091–4095.PubMedCrossRefGoogle Scholar
  54. 54.
    Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.Blood. 2002;100:3925–3929.PubMedCrossRefGoogle Scholar
  55. 55.
    Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins.J Endocrinol. 2002;175:41–54.PubMedCrossRefGoogle Scholar
  56. 56.
    De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays.Blood. 2001;98:771–780.PubMedCrossRefGoogle Scholar
  57. 57.
    Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1.Br J Haematol. 1996;94:318–323.PubMedCrossRefGoogle Scholar
  58. 58.
    Costes V, Magen V, Legouffe E, et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.Hum Pathol. 1999;30:1405–1411.PubMedCrossRefGoogle Scholar
  59. 59.
    Zimmermann P, David G. The syndecans, tuners of transmembrane signaling.Faseb J. 1999;13:S91-S100.PubMedGoogle Scholar
  60. 60.
    Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.Oncogene. 2002;21:2584–2592.PubMedCrossRefGoogle Scholar
  61. 61.
    Davis-Fleischer KM, Besner GE. Structure and function of heparin-binding EGF-like growth factor (HB-EGF).Front Biosci. 1998;3:d288–299.PubMedGoogle Scholar
  62. 62.
    Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGFrelated peptides in tumor growth.Front Biosci. 2001;6:D685–707.PubMedCrossRefGoogle Scholar
  63. 63.
    Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy.Oncogene. 2000;19:6550–6565.PubMedCrossRefGoogle Scholar
  64. 64.
    Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.Blood. 2002;99:1405–1410.PubMedCrossRefGoogle Scholar
  65. 65.
    Seidel C, Borset M,Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.Blood. 1998;91:806–812.PubMedGoogle Scholar
  66. 66.
    Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.Blood. 1999;94:3883–3888.PubMedGoogle Scholar
  67. 67.
    Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.Cancer Res. 1998;58:5640–5645.PubMedGoogle Scholar
  68. 68.
    Rasmussen T, Hudlebusch HR, Knudsen LM, Johnsen HE. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.Br J Haematol. 2002;117:626–628.PubMedCrossRefGoogle Scholar
  69. 69.
    Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.Nat Genet. 1997;16:260–264PubMedCrossRefGoogle Scholar
  70. 70.
    Sato N, Hattori Y, Wenlin D, et al. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.Jpn J Cancer Res. 2002;93:459–466.PubMedGoogle Scholar
  71. 71.
    Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.Mol Biol Cell. 2001;12:931–942.PubMedGoogle Scholar
  72. 72.
    Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.Blood. 2001;97:729–736.PubMedCrossRefGoogle Scholar
  73. 73.
    Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.Blood. 2002;100:3819–3821.PubMedCrossRefGoogle Scholar
  74. 74.
    Mackay F, Kalled SL. TNF ligands and receptors in autoimmunity: an update.Curr Opin Immunol. 2002;14:783–790.PubMedCrossRefGoogle Scholar
  75. 75.
    Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells.Nat Rev Immunol. 2002;2:465–475.PubMedCrossRefGoogle Scholar
  76. 76.
    Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma.Blood. 2002;100:2175–2186.PubMedCrossRefGoogle Scholar
  77. 77.
    Tarte K, Moreaux J, Legouffe E, Rossi JF, Klein B. BAFF is a survival factor for multiple myeloma cells.Blood. 2002Google Scholar
  78. 78.
    French JD, Walters DK, Jelinek DF. Transactivation of gp130 in myeloma cells.J Immunol. 2003;170:3717–3723.PubMedGoogle Scholar
  79. 79.
    Walters DK, French JD, Arendt BK, Jelinek DF. Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex.Oncogene. 2003;22:3598–3607.PubMedCrossRefGoogle Scholar
  80. 80.
    Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.J Biol Chem. 2003;278:5794–5801.PubMedCrossRefGoogle Scholar
  81. 81.
    Charrin S, Le Naour F, Oualid M, et al. The major CD9 and CD81 molecular partner. Identification and characterization of the complexes.J Biol Chem. 2001;276:14329–14337.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Bernard Klein
    • 1
  • Karin Tarte
    • 1
  • Michel Jourdan
    • 1
  • Karene Mathouk
    • 1
  • Jerome Moreaux
    • 1
  • Eric Jourdan
    • 2
  • Eric Legouffe
    • 3
  • John De Vos
    • 1
  • Jean François Rossic
    • 1
  1. 1.INSERM U475 and Unit for Cellular and Gene TherapyMontpellierFrance
  2. 2.Service de Médecine Interne BCHU de Nîmes, Nîmes
  3. 3.Service d’Hématologie et Oncologie MédicaleCHU Montpellier, Hôspital LapeyronieMontpellierFrance

Personalised recommendations